Saturday 17 October 2026
Export GUTS’s income statement to Excel — free account
Fractyl Health, Inc.
GUTS Healthcare Biotechnology
Fractyl Health, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $93,000.00, down 22.5% from fiscal 2023. In the quarter to June 2026, revenue fell 57.1%, EPS grew 71.9%, free cash flow grew 25.3% and total debt rose 1.54%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.55
2.61
−62.74%
Follow GUTS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 1,063.04% | (778.33%) | (744.17%) | (511.03%) |
+8 more TTM periods Free account |
|
| (146.75%) | (118.41%) | (122.85%) | (99.89%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(295.82%) | (205.18%) | (196.71%) | (189.09%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.52) | (0.55) | (1.20) | (1.34) | |
Free Cash Flow |
(82.43) | (87.73) | (90.88) | (86.81) | |
Capital Expenditures |
— | — | (0.56) | (0.79) | |
| Other line items | |||||
Cash ROIC |
(108.57%) | (76.50%) | (74.75%) | (82.48%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.78 | 0.81 | 0.64 | 0.71 | |
Depreciation/Fixed assets |
0.61 | 0.53 | 0.47 | 0.40 | |
Capex/Depreciation |
0.00 | 0.00 | (0.49) | (0.73) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.52) | (0.55) | (1.19) | (1.33) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates